Literature DB >> 12712411

When can cyclodextrins be considered for solubilization purposes?

Venkatramana M Rao1, Valentino J Stella.   

Abstract

This communication is intended to address the question: How can one determine, with minimum experimentation, if cyclodextrins (CDs) might be the right choice as solubilization enhancers for a given poorly water-soluble drug? The cyclodextrin utility number, U(CD), a dimensionless number, is introduced to assess the feasibility of the use of CDs in dosage forms. U(CD) is a lumped-parameter consisting of the dose of the drug, the workable amount of CD, the binding constant, and the drug solubility in the absence of CDs. U(CD) was been extended to ionizable drugs that show synergistic increase in solubility due to ionization and complexation. U(CD) is a guiding and not a predictive tool that the formulator can use. Copyright 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 92:927-932, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712411     DOI: 10.1002/jps.10341

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.

Authors:  Arik Dahan; Jonathan M Miller
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  High-throughput phase-distribution method to determine drug-cyclodextrin binding constants.

Authors:  Zhi Chen; Dujuan Lu; Stephen G Weber
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

4.  Effect of supersaturation on the oral bioavailability of paclitaxel/polymer amorphous solid dispersion.

Authors:  Linlin Miao; Yuheng Liang; Wenli Pan; Jingxin Gou; Tian Yin; Yu Zhang; Haibing He; Xing Tang
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

5.  Electrospun poly(ε-caprolactone) matrices containing silver sulfadiazine complexed with β-cyclodextrin as a new pharmaceutical dosage form to wound healing: preliminary physicochemical and biological evaluation.

Authors:  Sarah Oliveira Lamas Souza; Monique Alvarenga Pinto Cotrim; Rodrigo Lambert Oréfice; Suzana Gonçalves Carvalho; Jessyca Aparecida Paes Dutra; Francisco de Paula Careta; Juliana Alves Resende; Janaina Cecília Oliveira Villanova
Journal:  J Mater Sci Mater Med       Date:  2018-05-10       Impact factor: 3.896

6.  Oligodendroglial process formation is differentially affected by modulating the intra- and extracellular cholesterol content.

Authors:  Matthias Schmitz; Sandra C Signore; Inga Zerr; Hans H Althaus
Journal:  J Mol Neurosci       Date:  2012-06-28       Impact factor: 3.444

7.  Structure confirmation and thermal kinetics of the inclusion of cis-jasmone in β-cyclodextrin.

Authors:  Lvye Ai; Jingyan Hu; Xiaoming Ji; Huaxin Zhao
Journal:  RSC Adv       Date:  2019-08-21       Impact factor: 4.036

8.  Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.

Authors:  Victor Mangas-Sanjuan; Jorge Gutiérrez-Nieto; Magdalena Echezarreta-López; Isabel González-Álvarez; Marta González-Álvarez; Vicente-Germán Casabó; Marival Bermejo; Mariana Landin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.569

9.  Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.

Authors:  Avital Beig; Riad Agbaria; Arik Dahan
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

10.  Gold nanoparticles stabilized with βcyclodextrin-2-amino-4-(4-chlorophenyl)thiazole complex: A novel system for drug transport.

Authors:  I Asela; M Noyong; U Simon; J Andrades-Lagos; J Campanini-Salinas; D Vásquez-Velásquez; M Kogan; N Yutronic; R Sierpe
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.